Open App →
Back to News Feed
MIT September 15, 2026 By Antonio Regalado neutral

AI models need more data about biology, and OpenAI is paying to create it

OpenAIAI / LLMManufacturingRegulationEdge AI
Last year, the clinical trial policy analyst Ruxandra Teslo posted an idea for super-charging medical AI systems: use data from failed biotech companies. By bidding at their bankruptcy proceedings, she proposed, it might be possible to obtain detailed regulatory filings, manufacturing strategies, and safety data—information usually kept hidden as valuable trade secrets. She called these…
Read original article ↗

Related Articles

The AI Inference Revolution Is Here

Since about 2020, AI has largely focused on training bigger and better models. Large language models (LLMs) ballooned fr

IEEE Spectrum · September 15, 2026

ChatGPT transcripts are reportedly read by humans to improve responses, including those with personal information — 'Project Lilly' has seen OpenAI hire hundreds of contractors to manually review logs

404 Media reports that OpenAI has hired hundreds of contractors to evaluate ChatGPT responses manually.

Tom's Hardware · September 15, 2026

The Road Ahead: How Creators Are Combining OpenAI's GPT-6 Astra with Tripo AI for 3D Generation

SAN FRANCISCO, Sept. 14, 2026 /PRNewswire/ -- The official release of OpenAI's latest model, GPT-6 Astra, has ushered in

PR Newswire · September 15, 2026

OpenAI reportedly acquires AI camera startup Glass Imaging for more than US$300M

OpenAI has acquired Glass Imaging, a startup developing artificial-intelligence (AI) technology designed to improve smar

Digitimes · September 15, 2026